Tag: Serranator Alto
Cagent Vascular raises US$11.87M funding
Cagent Vascular has announced the completion of US$11.87 million in Series B funding. The round was led by two strategic investors including one that...
Serrenator Alto first-in-man PRELUDE study results presented at LINC 2018
Cagent Vascular, a developer of technology for vessel dilatation in cardiovascular interventions, has announced positive results from the first-in-human PRELUDE study of the company's...
Serranator PTA serration balloon catheter receives CE mark
Cagent Vascular has announced the issuance of its CE marking for the Serranator percutaneous transluminal angioplasty (PTA) serration balloon catheter. Cagent Vascular has also achieved...
Serranator Alto serration balloon effective at 30 days in treating critical...
Preliminary 30-day data from the PRELUDE trial investigating the use of the Serranator Alto percutaneous transluminal angioplasty (PTA) serration balloon catheter (Cagent Vascular) have...
